Chronic Recurrent Vogt–Koyanagi–Harada Disease and Development of ‘Sunset Glow Fundus’ Predict Worse Retinal Sensitivity

El‐Asrar, Ahmed M. Abu; Mudhaiyan, Tariq; Najashi, AlHatoon A. Al; Hemachandran, Suhail; Hariz, Rajab; Mousa, Ahmed; Al-Muammar, Abdulrahman

doi:10.3109/09273948.2016.1139730

Cited by 40 publications

(33 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Chronic recurrent VKH disease is significantly associated with more severe anterior segment inflammation at presentation and a worse visual acuity and mean retinal sensitivity at last follow‐up compared with initial‐onset acute VKH disease (Abu El‐Asrar et al. , ). Studies using laser flare‐cell meter demonstrated that both aqueous flare values and cell counts were significantly higher in patients with chronic recurrent VKH disease than those with initial‐onset acute VKH disease.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of ‘sunset glow fundus’ in initial‐onset acute uveitis associated with Vogt–Koyanagi–Harada disease

El‐Asrar

Dosari

Hemachandran

et al. 2016

Acta Ophthalmologica

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…) and mean retinal sensitivity (Abu El‐Asrar et al. ). In addition, the development of ‘sunset glow fundus’ was significantly associated with the development of any complication of cataract or glaucoma or subretinal neovascular membranes (Abu El‐Asrar et al.…”

Section: Discussionmentioning

confidence: 99%

Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of ‘sunset glow fundus’ in initial‐onset acute uveitis associated with Vogt–Koyanagi–Harada disease

El‐Asrar

Dosari

Hemachandran

et al. 2016

Acta Ophthalmologica

Self Cite

View full text Add to dashboard Cite

show abstract

“…The poor response to therapy, among patients with a chronic recurrent granulomatous AS inflammation has been described [ 20 , 25 ]. Moreover, this subset of patients has more complications [ 8 , 26 ] and a trend to have more severe ocular and systemic manifestations of the disease. El Asrar et al found a higher frequency of posterior synechiae and anterior chamber cells at diagnosis in patients who later turned to have this chronic condition [ 8 , 26 ].…”

Section: Diagnosismentioning

confidence: 99%

Initial-onset acute and chronic recurrent stages are two distinctive courses of Vogt-Koyanagi-Harada disease

Urzua

Herbort

Valenzuela

et al. 2020

J Ophthal Inflamm Infect

Self Cite

View full text Add to dashboard Cite

Purpose To describe distinctive stages of Vogt-Koyanagi-Harada (VKH) disease: initial-onset acute versus chronic recurrent disease. Methods A comprehensive literature review regarding stages and clinical presentations of VKH disease was conducted. Results Despite a list of signs that has been described as characteristic features of early or late phases of VKH disease, the current classification -developed by an international committee and published in 2001- does not consider a distinction regarding the time from onset of disease symptoms, and specific findings observed at certain time point from the symptoms presentation and outcomes related to the stage of VKH disease. In that sense, chronic recurrent VKH disease is more refractory to treatment and is associated with a higher rate of complications. Accordingly, this subset of VKH patients has poorer functional and anatomical outcomes than patients with an initial-onset acute disease. Conclusions An early clear distinction of VKH phenotype [Initial-onset acute versus chronic recurrent disease] should be considered in each clinical scenario, evaluating the delay in diagnosis and the clinical presentation, since it may help clinicians to perform a correct disease prognosis categorization and thus to make treatment decisions in terms of potential refractoriness or expected clinical outcomes.

show abstract

“…Following this initial uveitic phase, a significant group of patients may develop chronic granulomatous inflammation, and progressive depigmentation of the fundus resulting in "sunset glow fundus" appearance and/or chorioretinal atrophy (Figure 2). These clinical findings frequently result from insufficiently treated or from a late diagnosis, and they have been associated with poorer functional outcomes [19][20][21].…”

Section: Clinical Findingsmentioning

confidence: 99%

Vogt-Koyanagi-Harada disease

2020

Definitions

View full text Add to dashboard Cite

Vogt-Koyanagi-Harada (VKH) disease is an autoimmune disorder characterized by bilateral intraocular inflammation, exudative retinal detachments, and extraocular manifestations in the auditory, integumentary, and central nervous systems (CNS). This condition is driven by T-cell-mediated autoimmunity directed against melanocytes present in the uveal tissue, in a specific genetic context. The diagnosis is based on clinical presentation, accounting with a set of standardized diagnostic criteria. Studies have reported that patients who have a significant delay in the diagnosis and/or clinical signs of the chronic stage of the disorder have a poorer prognosis and thus special efforts have to be performed in order to have an early diagnosis, together with an appropriate treatment. In that sense, the development of tools that allow us to detect this disease and its degree of severity is extremely important. In this line, novel candidate biomarkers-such as quantification of mRNA levels of NOD and glucocorticoid receptor-have been recently reported, and they represent significant advances that can help the clinician to improve patient categorization and outcomes.

show abstract

Chronic Recurrent Vogt–Koyanagi–Harada Disease and Development of ‘Sunset Glow Fundus’ Predict Worse Retinal Sensitivity

Abstract: Chronic recurrent presentation and development of complications and 'sunset glow fundus' are associated with a worse sensitivity outcome.

Cited by 40 publications

References 35 publications

Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of ‘sunset glow fundus’ in initial‐onset acute uveitis associated with Vogt–Koyanagi–Harada disease

Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of ‘sunset glow fundus’ in initial‐onset acute uveitis associated with Vogt–Koyanagi–Harada disease

Initial-onset acute and chronic recurrent stages are two distinctive courses of Vogt-Koyanagi-Harada disease

Vogt-Koyanagi-Harada disease

Contact Info

Product

Resources

About